NEW YORK (GenomeWeb) – Illumina announced after the close of the market Wednesday that it plans to launch a $900 million convertible senior notes offering.

The firm said it proposes to offer $450 million of notes due 2019 and $450 million in notes due 2021. In addition, it intends to grant the initial purchasers a 30-day option to purchase up to an additional $67.5 million in aggregate principal amount of the notes due 2019 and an additional $67.5 million of the notes due 2021, which would bring the total potential offering size to around $1 billion.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.

Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.

In Nature this week: paternal age associated with de novo mutations in children, and more.

Nature News writes that researchers are still wrangling over the role of the p-value.